Basket cover image
18 handpicked stocks

Energy Markets On Edge: The Tariff Threat

President Trump's ultimatum to Russia, threatening tariffs on buyers of its oil, has sent shockwaves through energy markets. This creates a potential investment opportunity in non-Russian oil and gas companies poised to benefit from supply disruptions and higher prices.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+8

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juillet 30

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

COP

ConocoPhillips

COP

Current price

$93.76

BP

BP p.l.c.

BP

Current price

$33.82

EQNR

Equinor ASA

EQNR

Current price

$23.85

About This Group of Stocks

1

Our Expert Thinking

President Trump's ultimatum threatening 100% secondary tariffs on Russian oil buyers creates a major catalyst for global energy markets. This geopolitical disruption could fundamentally reshape supply chains and redirect demand to non-Russian producers, creating significant opportunities for alternative suppliers in stable regions.

2

What You Need to Know

This is an event-driven, tactical investment theme focused on near-term geopolitical volatility. The companies span the entire energy value chain from exploration to production services, primarily operating in politically stable regions outside of Russia. This positioning makes them well-suited to capture increased market share during supply disruptions.

3

Why These Stocks

These energy companies were specifically handpicked by professional analysts for their potential to benefit from Russian oil export disruptions. Each operates in stable regions and is positioned to capture redirected global demand and elevated prices that could result from major supply chain alterations in the energy sector.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+113.28%

Group Performance Snapshot

113.28%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 113.28% over the next year.

13 of 18

Stocks Rated Buy by Analysts

13 of 18 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

Geopolitical Catalyst in Motion

Trump's ultimatum creates immediate market-moving potential as global energy supply chains face unprecedented disruption. This isn't theoretical - it's happening now with a clear 10-12 day timeline.

🌍

Supply Chain Reshuffling Opportunity

When major oil suppliers face restrictions, demand doesn't disappear - it redirects to alternative sources. These companies are positioned in stable regions to capture that redirected flow and benefit from higher prices.

📈

Event-Driven Upside Potential

Professional analysts specifically curated this group to capitalize on near-term volatility and supply disruptions. These aren't random picks - they're strategic positions for a rapidly evolving energy landscape.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.